CLVT News & Events

Backs FY26 revenue view $2.3B-$2.42B, consensus $2.36B. Backs FY26 adjusted EBITDA view $980M-$1.04B. The company said, "We generated solid free cash flow of $79 million in the first quarter, reflecting strong Adjusted EBITDA performance and continued financial discipline. During the quarter, we used free cash flow and excess cash on hand to retire $143 million of debt, further strengthening our balance sheet. Based on our first-quarter performance and continued execution under the Value Creation Plan, we are reaffirming our full-year 2026 outlook, including expectations for margin expansion and approximately $400 million of free cash flow."

Reports Q1 revenue $585.5M, consensus $569.5M. The company said, "We are off to a solid start to 2026, with first-quarter results demonstrating tangible progress against the Value Creation Plan we launched in early 2025. Execution of the VCP is strengthening the quality and durability of our performance. We are simplifying and optimizing our business model, improving commercial effectiveness, and accelerating innovation across the portfolio. Together, these actions are expanding margins, increasing free cash flow generation, and improving the consistency of our results. AI is becoming a meaningful enabler of this progress, embedded in our products to enhance customer workflows and decision-making, and deployed internally to drive efficiency and scalability. With a more focused strategy and continued execution discipline, we remain confident in our ability to deliver sustainable growth and long-term value for shareholders."

Clarivate announced they will integrate Clarivate's proprietary regulatory intelligence with Claude's AI reasoning capabilities. The collaboration gives biopharma, biotech, medtech and clinical research organizations access to authoritative regulatory data within the AI workflows they already use.